Skip to main content
KOD
NASDAQ Life Sciences

Zenkuda and Tabirafusp-ted Both Hit Primary Endpoints in Pivotal DAYBREAK Trial

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$60.687
Mkt Cap
$2.033B
52W Low
$10.94
52W High
$47.842
52W Position info
455% above low
Off High info
at 52W high
Rel. Volume info
3.2× avg
Market data snapshot near publication time

KOD has more than doubled off its 52-week low of $10.94 on elevated volume (3.2× avg).

Summary

Kodiak Sciences announced that both Zenkuda and tabirafusp-ted met primary endpoints in the Phase 3 DAYBREAK trial for wet AMD. Zenkuda demonstrated 6-month durability in 54% of patients and a clean safety profile. The company plans a Q4 2026 BLA submission for Zenkuda across three indications.


Key Events · Product Development and Regulatory · KOD

  • Both Drugs Hit Primary Endpoints

    Zenkuda met the DAYBREAK primary endpoint with p=0.0007; tabirafusp-ted met its vision primary endpoint with p=0.0036 and anatomical key secondary endpoint with p<0.0001.

  • Zenkuda Shows 6-Month Durability

    54% of Zenkuda patients achieved a 24-week dosing interval at year one using strict treat-to-dryness retreatment criteria, with 0% intraocular inflammation and 0.5% cataract adverse event rate.

  • BLA Submission Planned Q4 2026

    Kodiak plans to submit a multi-indication BLA for Zenkuda in Q4 2026 covering five positive Phase 3 studies across wet AMD, diabetic retinopathy, and retinal vein occlusion.

  • KSI-101 Data Readout December 2026

    Topline data from the Phase 3 PEAK study of KSI-101 in macular edema secondary to inflammation is expected in December 2026, with a BLA filing planned for Q2 2027.


Analysis · KOD · Life Sciences

Both Zenkuda and tabirafusp-ted met their primary endpoints in the Phase 3 DAYBREAK trial for wet AMD. Zenkuda showed 54% of patients achieving 6-month dosing intervals and a 0% intraocular inflammation rate. The company plans a multi-indication BLA submission for Zenkuda in Q4 2026 covering five positive Phase 3 studies. This is a thesis-altering event for a precommercial biotech that had a going-concern warning as recently as August 2026 — positive pivotal data across multiple indications dramatically de-risks the pipeline and opens a path to commercialization.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KOD was trading at $60.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $10.94 to $47.84. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KOD - Latest Insights

KOD
Nov 12, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $108.12
Real-time Price: $110.55 info
Change: +$2.43 (+2%) info
Market Cap: $7.271B info
KOD
Nov 12, 2026, 4:00 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $108.25
Real-time Price: $110.55 info
Change: +$2.30 (+2%) info
Market Cap: $7.271B info
KOD
Nov 06, 2026, 4:55 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $99.30
Real-time Price: $110.55 info
Change: +$11.25 (+11%) info
Market Cap: $7.271B info
KOD
Oct 20, 2026, 5:19 PM EDT
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $92.97
Real-time Price: $110.55 info
Change: +$17.58 (+19%) info
Market Cap: $7.271B info
KOD
Sep 30, 2026, 4:29 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $94.50
Real-time Price: $110.55 info
Change: +$16.05 (+17%) info
Market Cap: $7.271B info